Clinical Trial

CsA+EPAG/HPAG+Romiplostim N01 in the Treatment of Newly-diagnosed SAA/TD-NSAA

Withdrawn Phase 2
View on ClinicalTrials.gov →
Why the trial stopped
The registration of this research plan was incorrect. A new registration has been re-applied for.
Summary
This study aimed to explore the efficacy and safety of cyclosporine (CsA) combined with eltrombopag (EPAG)/hetrombopag (HPAG) and romiplostim N01 in the treatment of newly-diagnosed transfusion-dependent aplastic anemia (TD-NSAA) and severe aplastic anemia (SAA)
Protocol Amendment History 3 changes
critical Trial status changed: Not Yet Recruiting → Withdrawn 2026-06-05
critical Reason stopped changed: — → The registration of this research plan was incorrect. A new registration has been re-applied for. 2026-06-05
notable Enrollment reduced: 43 -> 0 participants 2026-06-05
Trial Details
NCT Number NCT07523009
Lead Sponsor Peking Union Medical College Hospital
Conditions Severe Aplastic Anemia (SAA), Transfusion-dependent Non-severe Aplastic Anemia
Start Date 2026-06
Primary Completion 2028-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-04